AlveoliX Joins PANC-CKI Consortium

🌟 AlveoliX Joins PANC-CKI Consortium in Securing €4M Eurostars Grant for Pancreatic Cancer Research 🌟

Alveolix is pleased to be part of the PANC-CKI consortium, led by CasInvent Pharma, which has been awarded a €4M Eurostars grant.

Competing with participants from 37 countries, the project achieved number one ranking in the Czech Republic, Switzerland, and France, with a score of 51/54.

This project aims to develop a novel CK1 inhibitor for pancreatic cancer treatment, utilizing AI-driven digital twins, patient-derived organoids, and AlveoliX ‘s organs-on-chip technology.

We look forward to contributing to this important effort in advancing pancreatic cancer research!

Don’t wait and read the full press release here!